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vaccine
Abstract
QUESTION UNDER STUDY: To assess clinical reactions, immune responses and adverse events to
undiluted, three- and sixfold diluted Lister strain vaccine stockpiled in Switzerland. METHODS: A
prospective, triple-blinded, randomised, parallel group clinical trial was performed. RESULTS: From
2001 to 2007 104 persons with an indication for vaccinia vaccination were recruited. They had a median
age of 33 years (range 18-65), 56 (53.8%) were re-vaccinees and 48 (46.2%) primary vaccinees. There
was no statistically significant variation in the proportion of revaccinees between diluted and undiluted
vaccine groups (75% vs 51%, p = 0.118). With an overall clinical take rate (major reaction) of 97.1%
the majority of the vaccinia-naïve participants exhibited an at least fourfold increase of neutralising
antibody titres (32/38, 84.2%) post-vaccination. Interestingly this proportion was lower among
re-vaccinees (29/46, 63.0%, p = 0.048). No significant difference was observed in the take rate or at
least fourfold seroconversion rate between the threefold and sixfold diluted vaccine doses. Adverse
events were reported by 98 (94.2%) participants, not accounting for itching at the vaccination site.
CONCLUSION: Subjects requiring immunisation were successfully (re-) vaccinated with undiluted as
well as with three- or sixfold diluted vaccinia vaccine. Our findings complement previous studies with
respect to the clinical take rate and immune response. The rate of adverse events was substantial but not
unexpected and no severe adverse events occurred. In conclusion, the existing smallpox vaccine
stockpile might be expanded by administering three- or sixfold diluted vaccine doses combined with a
careful pre-vaccination screening and extensive instructions to vaccinees.
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Question under study: To assess clinical reac-
tions, immune responses and adverse events to
undiluted, three- and sixfold diluted Lister strain
vaccine stockpiled in Switzerland. 
Methods: A prospective, triple-blinded, ran-
domised, parallel group clinical trial was per-
formed.
Results: From 2001 to 2007 104 persons with
an indication for vaccinia vaccination were re-
cruited. They had a median age of 33 years (range
18–65), 56 (53.8%) were re-vaccinees and 48
(46.2%) primary vaccinees. There was no statisti-
cally significant variation in the proportion of re-
vaccinees between diluted and undiluted vaccine
groups (75% vs 51%, p = 0.118). With an overall
clinical take rate (major reaction) of 97.1% the
majority of the vaccinia-naïve participants exhib-
ited an at least fourfold increase of neutralising
antibody titres (32/38, 84.2%) post-vaccination.
Interestingly this proportion was lower among re-
vaccinees (29/46, 63.0%, p = 0.048). No significant
difference was observed in the take rate or at least
fourfold seroconversion rate between the three-
fold and sixfold diluted vaccine doses. Adverse
events were reported by 98 (94.2%) participants,
not accounting for itching at the vaccination site.
Conclusion: Subjects requiring immunisation
were successfully (re-) vaccinated with undiluted
as well as with three- or sixfold diluted vaccinia
vaccine. Our findings complement previous stud-
ies with respect to the clinical take rate and im-
mune response. The rate of adverse events was
substantial but not unexpected and no severe ad-
verse events occurred. In conclusion, the existing
smallpox vaccine stockpile might be expanded by
administering three- or sixfold diluted vaccine
doses combined with a careful pre-vaccination
screening and extensive instructions to vaccinees.
Key words: smallpox vaccine; vaccinia; take rate;
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Summary
In Switzerland widespread vaccination
against smallpox ceased in 1974 with few differ-
ences between cantons. Vaccination was main-
tained for risk groups only, especially for trav-
ellers. The last naturally infected case was regis-
tered 1977 in Somalia. In May 1980, WHO de-
clared that a world free of smallpox illustrated the
success of a comprehensive global vaccination
strategy [1].
In the past few years, smallpox has been rated
among the top four microbial agents that are
“likely to be used” in a bioterrorist attack [2–4].
Although no longer licensed in Switzerland,
smallpox vaccine consisting of live vaccinia virus
strains offers cross-protection against variola
viruses and monkeypox virus infections. 
Smallpox vaccine provides a unique opportu-
nity for investigating immune response character-
istics after primary or re-vaccination decades
apart, as well as for studying the duration of de-
tectable immune responses in the absence of ex-
posure history to variola virus [5]. According to
previous studies mainly performed with the U.S.
Dryvax vaccine, a long-lasting humoral and cell-
mediated immune memory to vaccinia exists in
previously vaccinated individuals. Further it was
shown, that undiluted as well as diluted vaccine
formulations would lead to successful clinical and
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immune responses to vaccination [6–10]. How-
ever, up to now there have only been three studies
providing data on the Lister strain vaccinia vac-
cine stored in Switzerland [11–13].
Our aims were: 
– to assess descriptively clinical and immune re-
sponses and adverse events to use of the
smallpox vaccine stockpiled in Switzerland.
– to evaluate clinical, epidemiological and ad-
verse event parameters for three- and sixfold
diluted smallpox vaccine doses. The rationale
behind this approach is the fact that the Swiss
supply of three million vaccine doses may
need to be stretched in case of an emergency
to make it available for all ~7.2 million resi-
dents.
Methods
Vaccine and administration
The vaccine and diluent were obtained from the
Swiss Armed Forces Pharmacy, Ittigen, Switzerland. The
vaccine was produced in 1982 or earlier and consists of
the vaccinia virus Lister strain, Lister Institute, Elstree,
UK. Having been kept lyophilised at -20 °C the vaccine
was tested to assess its potency and stability following
more than two decades [2]. The reconstituted undiluted
vaccine lots contained a measured vaccinia virus titre of
>108 plaque forming units (pfu)/ml in a phosphate-
buffered, glycerol-containing solution. For preparing the
threefold and sixfold dilutions at the vaccination centre
the same diluent was used.
The vaccine was administered with a bifurcated nee-
dle using the 15-puncture technique [14] in the deltoid
region of the upper arm or in the inguinal region consid-
ering participants’ preference. Subsequently, the vaccina-
tion site was covered with a semi-occlusive bandage
(Tegaderm, 3M Health Care, St. Paul, MN, USA) [15].
Detailed instruction was given on how to care for the vac-
cination site to prevent spread of the virus either within
the vaccinees or to a close contact by inadvertent inocula-
tion. Bandage material was provided until resolution of
the local reaction. For questions regarding adverse events,
health status or contact transmission a professional hot-
line was available 24/7.
Study design and subjects
A prospective triple-blind, randomised, parallel-
group clinical trial was conducted at the Vaccination Cen-
tre of the University of Zurich, Zurich, Switzerland.
Healthy subjects, aged 18–65 years, were eligible in
Switzerland if they reported an occupational exposure
risk, such as laboratory workers working with non-highly
attenuated vaccinia viruses, military personnel or human-
itarian personnel designated to serve in the Iraq crisis ac-
cording to expert advice. To ensure practicability and to
set higher power at the diluted vaccines batches of 1:1, 1:3
and 1:6 dilutions were randomly assigned to the vaccina-
tion dates in a ratio of 1:4:2. Simple randomisation was
used to allocate the vaccination dates to the vaccine dilu-
tions with a computer generated randomisation list. The
allocation sequence was concealed by a pharmacist as a
“third party”. Study subjects, study staff administering the
vaccine as well as the laboratory personnel were unaware
of the vaccine dose assigned.
Participants were invited to sign an informed consent
and they were carefully screened for the presence of the
following exclusion criteria: smallpox vaccination in the
past three years, acute febrile illness (>38.0 °C axillary tem-
perature), history of atopic dermatitis, eczema or an acute
exfoliative or chronic skin condition, history of seizure dis-
orders or malignancy, pregnancy or breast feeding and al-
tered immunocompetence among both vaccinees or their
close contacts. History of heart disease or at least three
risk factors, known allergy to vaccine components and ad-
ministration of any live vaccines in the past 30 days were
assessed for study subjects only [16]. By using question-
naires baseline demographic characteristics and the med-
ical history were assessed while general and vaccinia vacci-
nation history were based on vaccination certificates or on
the presence of a vaccination scar (vaccinia). 
Vesicle formation, health status and adverse events
were monitored immediately (15 min post-vaccination)
and on days 7, 14 and 28 post-vaccination by follow-up
visits or by questionnaires. In case of systemic adverse
events follow-ups were done until restitutio ad integrum.
Serum samples were collected at baseline (day 0) and 24
to 35 days post-vaccination (day 28) to determine anti-
body-based seroconversion rate. Due to time constraints
no preimmunisation serum samples were collected from
the subjects receiving the undiluted vaccine.
Approval was given by the Ethical Committee of the
Canton of Zurich and the study was registered at
Swissmedic, Berne, Switzerland. 
Clinical assessment
Primary endpoint was the clinical response rate ac-
cording to the WHO criteria [14]. A major reaction was
defined as a vesicular or pustular lesion or an area of defi-
nite palpable induration or congestion surrounding a cen-
tral lesion that might be a crust or an ulcer. Vaccine “take”
corresponded to the presence of a major reaction exam-
ined 6–8 days after vaccination. An overall take rate 090%
was considered to be sufficient. Local or systemic adverse
events and serological testing were recorded as secondary
endpoints. 
Laboratory assessment
By the previously described plaque reduction assay
titres of vaccinia-specific neutralising antibodies were
measured in pre- and post-vaccination sera [17, 18]. In
short, two-fold serial dilutions of pre- and postimmunisa-
tion serum samples with 50 pfu of vaccinia Lister were in-
cubated for two days and plaque formation analysed fol-
lowing staining with crystal violet solution. Antibody titre
was determined as the dilution step causing a 50% vac-
cinia plaque reduction compared to the number of
plaques obtained with a negative serum. 
Statistical methods
Statistical analyses were done with Stata version 8.2.
Two-sided Fisher’s exact test (for binary outcomes) or
Wilcoxon rank sum tests (for continuous outcomes) were
used for pair-wise comparisons of differences between
groups. The level of statistical significance was set at 
p <0.05 and all tests were two-sided. Overall effects were
examined by multivariate logistic regression analyses.
392-397 Gass 11966.qxp  27.6.2008  16:02 Uhr  Seite 393
394Clinical and immune responses to smallpox vaccine
Study population
Between the end of 2001 and 2007, a total of
113 subjects presented themselves; 104 were re-
cruited and 9 exhibited exclusion criteria (fig. 1).
There was an average of 6.5 vaccinees on the 
16 vaccination dates (range: 3–13). Of those, 56
(53.8%) were re-vaccinees (vaccinia non-naïve,
last vaccination 6–55 years ago with a median of
33.7 years) and 48 (46.2%) primary vaccinees
(vaccinia-naïve) with 102 (98.1%) being Western
Europeans, one participant originating from
China and another one from New Zealand. 
Among the primary vaccination cohort the
median age was 28 years (range 18–51 yrs) and
there were 23 (47.9%) females. The demographic
structure significantly differed with respect to age
and gender in the re-vaccinated cohort with a me-
dian age of 45 years (range 28–65 yrs) and with 9
(16.1%) females (p = 0.001). Regarding the demo-
graphic characteristics no statistically significant
differences between the dilution groups were ob-
served (table 1). 
Clinical reaction
All but three subjects showed a major reac-
tion at the vaccination site (101, 97.1%) on day 7.
There was no evidence for a vaccination failure
for these re-vaccinated participants (one vacci-
nated once, 15 years ago, the two others were vac-
cinated twice each, 51 and 30 and 47 and 38 years
ago, respectively). They showed pre-existing neu-
tralising antibodies and a twofold titre increase
post-vaccination. In addition, no other character-
istics distinguished these three re-vaccinees from
the cohort. Overall, there was no statistical differ-
ence in the take rate between the groups receiving
different vaccine dilutions (table 2).
The average size of the vaccination lesion
peaked in the second week following smallpox
vaccination. Most of the primary vaccinees de-
scribed vaccination site progressing from vesicle
to pustule and scab formation. Probably due to
the semi-occlusive dressing, drying was delayed
for a couple of days until formation of a scab was
observed. In addition, redness due to the adhesive
of the bandage was occasionally reported. Previ-
ously vaccinated subjects showed on average not
only a smaller pustule but also a more rapid reso-
lution of the vaccination site than the primary
vaccinees. All vaccination lesions had resolved by
days 28 to 35.
Antibody response to vaccinia vaccination: 
The majority of the vaccinia-naïve partici-
pants exhibited an at least fourfold titre increase
(32/38, 84.2%) whereas this proportion was lower
among re-vaccinees (29/46, 63.0%, p = 0.048). The
average titre of neutralising antibodies post-vacci-
nation was similar among primary and re-vacci-
nated individuals and significantly higher than be-
fore vaccination. No significant difference in the
seroconversion rate between the threefold and
sixfold diluted vaccine dose was observed (p =
0.447) (table 2). Six primary vaccinees and 17 pre-
Results
 
     Eligible subjects 
n = 113 
Enrolled subjects 
n = 104 
Vaccine dilution  
randomly assigned to 
date of intervention 
Excluded subjects 
n = 9  
(history of eczema or 
atopic dermatitis: 5, 
close contact with 
pregnant or children 
1yr: 4) 
Missing blood samples: 
n = 6 
(time constraints linked 
to travel/Iraq crisis: 4, 
withdrawal: 2) 
Lost to follow-up: n = 0 
Exclusion to analysis: 
n = 0 
Missing blood samples: 
n = 2 
(time constraints, travel-
related: 2) 
Lost to follow-up: n = 0 
Exclusion to analysis: 
n = 0 
 
Allocated to undiluted 
vaccine: 
n = 12 
Received allocated 
intervention 
n = 12 
Missing blood samples: 
n = 12 
(time constraints linked 
to Iraq crisis: 12) 
Lost to follow-up: n = 0 
Exclusion to analysis: 
n = 0 
 
Allocated to threefold 
diluted vaccine: 
n = 64 
Received allocated 
intervention 
n = 64 
Allocated to sixfold 
diluted vaccine: 
n = 28 
Received allocated 
intervention 
n = 28 
Figure 1
Recruitment scheme.
Factor Total Dilution p-value1
1:1 1:3 1:6
n = 104 (%) n = 12 (%) n = 64 (%) n = 28 (%)
Gender: male 72 (69.2) 7 (58.3) 47 (73.4) 18 (64.3) 0.457
Age (years): median (range) 33.0 (18–65) 42.2 (30–64) 39.5 (24–65) 33.1 (18–64) 0.001
Origin
European 102 (98.1) 12  (100.0) 63 (98.4) 27 (96.4) 0.518
Actual / chronic disease 8 (7.7) 3 (25.0)2 3 (4.7)3 2 (7.1)3
Medication at enrolment 6 (5.8) 1 3 (4.7) 2 (7.1)
Topical (skin) 2 14 15 0
Oral 4 0 26 27
1 p-values for the comparison of 1:3 and 1:6 dilutions by use of Fisher’s exact test
2 arm fracture, hay fever, acne
3 hypertension, prostate hyperplasia, hypothyroidism, hypertension, shingles
4 acne lotion 
5 antiviral lotion
6 antihypertensive medication, a-inhibitor
7 antihypertensive and anti-hypothyroidism-related medication
Table 1
Demographic and
medical characteris-
tics of the study par-
ticipants (n = 104).
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viously vaccinated subjects failed to show a four-
fold increase in antibody titres but for 20 (87%)
of them a major reaction was observed. In addi-
tion, baseline neutralising antibodies were more
frequently detected among previously vaccinated
individuals than among primary vaccinees (16/46,
34.8% vs 5/38, 13.1%; p =  0.022). The increases
in neutralising antibody titres were correlated
neither to the size of the cutaneous reaction nor
to the vaccine dilution administered nor to the
rate of adverse events reported.
Adverse events following vaccinia vaccination:
A total of 98 (94.2%) participants reported
any adverse events not considering itching (table
3). Most of them were confined to anticipated,
more local reactions including lymphadenopathy.
Itching was more prominent among subjects re-
ceiving diluted vaccine doses. Notably, systemic
adverse events occurred in 40.4% (42/104) mostly
referring to flu-like symptoms such as headache,
fever and muscle pain. Interestingly, there was no
significant difference among vaccinia-naïve and
non-naïve vaccinees neither in the distribution of
reported side effects nor with respect to the num-
ber of adverse events recorded. Although, a ten-
dency was observed towards less frequent local
adverse events among vaccinia-experienced sub-
jects compared to primary vaccinees. These dif-
ferences were mainly restricted to local com-
plaints of pain and tenderness at the vaccination
site. No significant difference of adverse events
was observed when considering three- or sixfold
vaccine dilution.
Five participants consulted a physician, all
these primary vaccinees suffered from systemic
symptoms such as headache, chills or fever. Four
of them were diagnosed with a robust take ac-
cording to the definition for suspected cases [19]
and one with a suspected superinfection at the in-
jection site following smallpox vaccination [19].
Intake of medication was reported by eight vacci-
nees with five individuals having taken analgesics
and three having declared antibiotic treatment for
potential superinfection. One episode of vaccina-
tion-related transient arthritis resolved com-
pletely following a short-term high-dose corticos-
teroid therapy.
Multivariate logistic models were constructed
for all groups of adverse events because gender,
age and history of smallpox vaccination were
strongly interrelated due to the previous national
vaccination recommendations. None of these
variables were significantly related to the pres-
ence of any local or systemic adverse events as was
already shown in the bivariate analysis.
Table 2
Clinical reaction and antibody response after vaccination with undiluted or diluted vaccinia vaccine Lister strain (n = 104).
Vaccine Major reaction Vesicle Mean At least 4fold increase Titre pre-vaccination Titre post-vaccination p-value3
(take; %) diameter (mm) of antibody titre (%)1 Mean±SD2 Mean±SD2
Total (n = 104) 101 (97.1) 9.4±4.2 61/84 (72.6) 0.98±0.98 4.39±2.14 0.000
Undiluted  (n = 12) 12 (100.0) 9.7±1.5 n/a n/a n/a
1:3 diluted (n = 64) 62 (96.9) 9.7±4.7 43/58 (74.1) 0.97±0.97 4.18±2.11 0.000
1:6 diluted (n = 28) 27 (96.4) 8.6±2.8 18/26 (69.2) 1.02±1.04 4.85±2.18 0.000
1 The total per group is below n = 64 and n = 28, respectively due to missing blood samples as depicted in figure 1
2 data presented as log2 mean titre. Samples with no detectable activity at 1:2 dilution are assigned to a value of 0.5 log2
3 comparison of pre-/post-vaccination titres by Wilcoxon sign rank test
n/a: data not available
Symptom Dilution 
n (%)
Total 1:1 1:3 1:6 p-value
(n = 104) (n = 12) (n = 64) (n = 28)
Any symptom excluding itch 98 (94.2) 12 (100.0) 61 (95.3) 25 (89.3) 0.436
No. of symptoms reported
0 2 (1.9) 0 (0.0) 1 (1.6) 1 (3.6)
1 33 (31.7) 7 (58.3) 14 (21.9) 12 (42.9)
>1 69 (66.4) 5 (41.7) 49 (76.5) 15 (53.5)
Any local symptom 95 (91.3) 12 (100.0) 59 (92.2) 24 (85.7) 0.547
Itching 50 (48.1) 2 (16.7) 34 (53.1) 14 (50.0) 0.065
Lymphadenopathy 95 (91.3) 12 (100.0) 59 (92.2) 24 (85.7) 0.547
Any systemic symptom 42 (40.4) 1 (8.3) 29 (45.3) 12 (42.8) 0.051
Gastrointestinal 3 (2.9) 1 (8.3) 1 (1.6) 1 (3.6)
Fever 21 (20.2) 1 (8.3) 14 (21.9) 6 (21.4) 0.627
Flu-like symptoms 29 (27.9) 1 (8.3) 20 (31.2) 8 (28.6)
Table 3
Frequency of local
and systemic adverse
events following
smallpox vaccination
(n = 104). 
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Most importantly, our results suggest that the
current stocks of vaccinia virus Lister strain can
be diluted at least sixfold and still induce a major
cutaneous reaction in more than 95% of the vac-
cinees. This finding is generally in accordance
with recent studies from Israel, Taiwan, and
Korea [11–13] which report take rates of less than
100% for a tenfold dilution of the Lister strain
vaccine corresponding to an estimated virus titre
of at least 106.6 pfu/ml. Similar success rates were
also described for the New York City Board of
Health strain as well as in studies performed
decades ago [6–10, 20–21]. As a limitation of this
study and due to the small dilution group sizes a
difference could not be established in a superior-
ity trial. From a practical point of view, the high
take rates among all vaccinees are essential.
There was no clear correlation between anti-
body responses and cutaneous reaction at the vac-
cination site. Whereas the clinical take rate as a
marker of protection following smallpox vaccina-
tion has been validated throughout its history, im-
munological correlates of protection are not ex-
actly defined but are considered to involve a com-
bination of humoral and cell-mediated responses
[5, 9]. Of note, also individuals vaccinated more
than 25 years ago with low pre-existing antibody
titres revealed a clinical take rate exceeding 90%
which demonstrates potency of the diluted vac-
cine in this group. It is controversial whether this
detectable but declined humoral immunity would
protect against smallpox or would reduce disease
severity [22]. Therefore, the characteristics of the
population unresponsive to the vaccine need fur-
ther exploration. In this context, emphasis has to
be placed on instructing the vaccination tech-
nique carefully. Actually, there exist no similar,
routinely applied immunisation procedures and
therefore, training and practical experience are
essential. 
Adverse events
The reported rate of local and systemic ad-
verse events is high when compared to previous
studies [6-9, 11, 12, 23–25] but not unusual [10,
13]. However, the local reactions at the vaccina-
tion site were anticipated and their duration was
limited. Due to the small sample size, the high
proportion of previously vaccinated subjects and
the under-representation of younger people com-
parisons between different vaccine dilution
groups are limited. Especially, we fail to demon-
strate that less severe or a lower rate of systemic
adverse events are attributed to the diluted vac-
cine doses. However, it seems plausible and was
shown several times, that vaccine dilution as well
as vaccination history reduce not only the rate of
adverse events but also the severity of side effects
[6, 7, 10, 20]. Here, no significant difference in the
rate of adverse events was detected among three-
or sixfold diluted vaccine doses. 
None of the study participants experienced
any of the rare, severe adverse events previously
associated with smallpox vaccines, such as eczema
vaccinatum, postvaccinial encephalitis or progres-
sive vaccinia. However, these complications gen-
erally occurred at a rate of one to 25 cases per
million [26] and therefore, would not be likely to
be found in a study of this size. In addition, care-
ful pre-vaccination screening has been shown to
efficiently reduce the rate of these known severe
adverse events [10, 27]. By excluding individuals
at risk of cardiac-related events, atopic dermatitis
and immunosuppressive disorders smallpox vac-
cine can be administered with minimised risk.
However, the rate of adverse events reported for
this smallpox vaccine would not be acceptable for
the actual routinely used vaccines. In the view of
these concerns about vaccine safety there is de-
mand for the development of newer, safe but still
efficacious smallpox vaccines especially to achieve
bioterrorist preparedness.
Our thanks go to all participants and we are indepted
to the study nurses for their assistance throughout the
study.
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